The activity of enzymes originally involved in glycolysis is impaired in LKB1 mutant tumor cells; The combination of HDAC6 inhibitor and glutaminase inhibition can enhance the killing of LKB1 mutant tumor cells and anti-tumor efficacy. Here, STK11 is linked to neoplasm.